United States

  • Research/Demonstration Projects: Numerous demonstration projects and implementation pilots in a range of populations are ongoing or planned in the US, while a handful have already completed and reported results. Several iPrEx trial sites were in the US and ongoing research on non-TDF-based PrEP and alternative dosing regimens are ongoing at sites in the US.
  • Drug Registration: In July 2012, the US Food and Drug Administration approved daily oral Truvada for HIV prevention.
  • Policy/Regulatory: PrEP is part of the updated US National HIV/AIDS Strategy (NHAS), released in July 2015, as a component of HIV prevention. A federal action plan that provides information on how it will be operationalized is expected in December 2015.
  • Advocacy: Advocacy for PrEP in the US has been ongoing across a number of groups for several years, supporting the research effort, calling for early implementation, FDA approval, guidance for all populations and now expanded access. A coalition of individuals and groups continue the work on social media and via the online PrEP Access Advocates list (to join, email here).
  • US Women & PrEP Working Group: This group represents organizations and individuals pushing for programming and access to PrEP for women. Learn more.
  • United States Local Programs: For information on specific local programs in the US, click here.

Last updated on September 1, 2017.

News Spotlight